Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Wolff

Showing results (71-80 of 123) with videos related to

Pageof 13
Sort By:
Pharmacoeconomics|November 28, 2017
Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBram L T Ramaekers, Robert Wolff, Anoukh van Giessen, et al.
Pharmacoeconomics|October 27, 2022
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBen Wijnen, Willem Witlox, Robert Wolff, et al.
Clinical Colorectal Cancer|July 30, 2014
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancerVan Morris, Michael J Overman, Zhi-Qin Jiang, et al.
Plos One|June 7, 2018
Repeated in-field radiosurgery for locally recurrent brain metastases: Feasibility, results and survival in a heavily treated patient cohortPanagiotis Balermpas, Susanne Stera, Jens Müller von der Grün, et al.
Pharmacoeconomics|February 21, 2026
NICE Appraisals of Relugolix-CT and Linzagolix for Endometriosis Symptom Management: Commentary on Clinical and Economic UncertaintiesVenetia Qendri, Maiwenn Al, Annemieke van Dongen-Leunis, et al.
Cancers|August 12, 2023
Hepatic Metastasectomy in Squamous Cell Carcinoma of the Anal Canal: A Case Series of a Curative ApproachJane E Rogers, Amanda Sirisaengtaksin, Michael Leung, et al.
Annals of Surgical Oncology|June 25, 2011
Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trialMatthew H G Katz, Robert Wolff, Christopher H Crane, et al.
Pharmacoeconomics|October 19, 2021
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalSabine E Grimm, Willem Witlox, Robert Wolff, et al.
Pharmacoeconomics|April 2, 2022
Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalSabine E Grimm, Willem Witlox, Robert Wolff, et al.
Pharmacoeconomics|December 10, 2019
Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalWillem J A Witlox, Antoinette D I van Asselt, Robert Wolff, et al.
Pageof 13

Showing results (71-80 of 123) with videos related to

Sort By:
Pageof 13
Pharmacoeconomics|November 28, 2017
Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBram L T Ramaekers, Robert Wolff, Anoukh van Giessen, et al.
Pharmacoeconomics|October 27, 2022
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBen Wijnen, Willem Witlox, Robert Wolff, et al.
Clinical Colorectal Cancer|July 30, 2014
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancerVan Morris, Michael J Overman, Zhi-Qin Jiang, et al.
Plos One|June 7, 2018
Repeated in-field radiosurgery for locally recurrent brain metastases: Feasibility, results and survival in a heavily treated patient cohortPanagiotis Balermpas, Susanne Stera, Jens Müller von der Grün, et al.
Pharmacoeconomics|February 21, 2026
NICE Appraisals of Relugolix-CT and Linzagolix for Endometriosis Symptom Management: Commentary on Clinical and Economic UncertaintiesVenetia Qendri, Maiwenn Al, Annemieke van Dongen-Leunis, et al.
Cancers|August 12, 2023
Hepatic Metastasectomy in Squamous Cell Carcinoma of the Anal Canal: A Case Series of a Curative ApproachJane E Rogers, Amanda Sirisaengtaksin, Michael Leung, et al.
Annals of Surgical Oncology|June 25, 2011
Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trialMatthew H G Katz, Robert Wolff, Christopher H Crane, et al.
Pharmacoeconomics|October 19, 2021
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalSabine E Grimm, Willem Witlox, Robert Wolff, et al.
Pharmacoeconomics|April 2, 2022
Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalSabine E Grimm, Willem Witlox, Robert Wolff, et al.
Pharmacoeconomics|December 10, 2019
Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalWillem J A Witlox, Antoinette D I van Asselt, Robert Wolff, et al.
Pageof 13